Evidence from the Childhood Cancer Survivor Study suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators led the research, which will be presented today at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
The study is one of four being featured at the plenary session press briefing, which highlights research that ASCO deems as having the highest scientific merit and greatest potential to affect patient care.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7532851-st-jude-cancer-research/
When Amway™ asked for help in raising awareness about global childhood malnutrition through its Nutrilite™ Power of 5 Campaign, more than 260,000 people across the globe raised their hand to do just that. And they broke a GUINNESS WORLD RECORDS™ title in the process.
As a global leader in nutrition research, development and innovation, Amway paired its expertise from Nutrilite™, the world’s number one selling vitamins and dietary supplements brand*, with its passion for helping people live better lives. Amway™ last year launched the Nutrilite™ Power of 5 Campaign to expand the distribution of the Nutrilite™ Little Bits™ supplement. At the time, the micronutrient powder with 15 essential vitamins and minerals for children was being distributed in two countries through established programs run by Non-Governmental Organizations. It has since expanded to nine countries and there are plans for more.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7214653-amway-guinness-world-record/
Currently melanoma is the deadliest form of skin cancer and one of the most common cancers in women under 40 years old in the United States. The first line of defense in helping to reduce the risk of developing melanoma is by wearing broad spectrum UVA and UVB SPF protection. L’Oréal Paris, a leading global beauty brand, and Melanoma Research Alliance (MRA), the leading private funder of melanoma research, announced today the launch of It’s THAT Worth It To Me. This social media campaign encourages women to donate 15 social media seconds by sharing why SPF protection or using sunless tanner is worth it to protect their skin, their beauty and their life. For every social share, L’Oréal Paris will donate $1 to MRA to fund the L’Oréal Paris - MRA Team Science Award Research Grant, up to $250,000 in 2015.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7459051-l-oreal-paris-mra-it-s-that-worth-it/
AARP Travel, a valuable resource for America's 76 million baby boomers who spend over $120 billion annually in leisure travel, today announced new insights into Multi-Generational family vacations (www.aarp.org/multigenvacation) - trips that include three generations or more, such as kids, parents, aunts/uncles and grandparents all traveling to one destination to vacation together.
The new research conducted by AARP Travel of people 45 and older offers valuable insights into multi-generational vacations including why families are going, where they're going, what they do on these family vacations, the challenges to plan them and why they create memories of a lifetime. AARP is also giving away a family vacation for six for an Alaskan cruise, Grand Canyon adventure, or Hawaiian getaway to one lucky sweepstakes winner. A daily prize drawing is also held and each day one winner will receive a gift card. Visit http://www.aarp.org/travelsweeps to participate in the sweepstakes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7488431-aarp-travel/
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
When asked how they feel about mixing their work and personal lives, 58% of Generation Mobile workers feel guilty, according to new research from MobileIron. The MobileIron Gen M Survey, a global study of more than 3,500 full- and part-time professionals who use a mobile device for work, highlights an emerging demographic in the workplace: Generation Mobile or “Gen M.” The study found that Gen M, which is composed of mobile workers who are either men age 18-34 or people with children under age 18 in their households, relies more heavily on mobile technologies than the general population to mix their work and personal activities.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7423151-mobileiron-gen-m-study-mobile-guilt/
At a time when cotton’s market share is threatened by synthetics, Cotton Incorporated responds with authenticity. The latest offerings in the 26-year run of the highly-regarded The Fabric Of Our Lives™ campaign from the not-for-profit research and promotion company focus on individual consumers and their personal stories of why cotton apparel items are their favorites.
Introducing the tagline, “Cotton. It’s Your Favorite for a Reason(SM),” the first commercial will launch on April 20 with thirty- and fifteen-second spots; additional commercials will be rolled out over the course of the year. The campaign also includes: a digital video series of consumer stories, some expanding on the stories told in the commercials; a unique, cotton-focused collaboration with online retailer Rue La La and a trade print advertisement.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7490551-new-cotton-incorporated-campaign/
Every three minutes someone in the U.S. is diagnosed with a blood cancer. No one knows this better than “Nashville” star Charles Esten and his wife Patty. Esten’s 15-year-old daughter, Addie, was diagnosed with leukemia at age 2 ½. Naturally, their world was turned upside down. But, they quickly learned that there was hope, based on research to advance new treatments and cures for leukemia, much of it funded by The Leukemia & Lymphoma Society (LLS).
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7491051-charles-esten-light-the-night-walks/
Patients and scientists from across the country are featured in the latest “From Hope to Cures” ad campaign launched today by the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents the country’s leading biopharmaceutical researchers and biotechnology companies.
This continuation of PhRMA’s “From Hope to Cures” campaign, first launched in January 2014, highlights the value biopharmaceutical innovation provides to patients, society and the economy. The latest ad campaign, featuring print, radio and digital advertising, highlights the stories of patients who benefit from the medicines developed by biopharmaceutical companies and the scientists who work every day to develop life-saving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350552-phrma-from-hope-to-cures/
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
Virginia Bioinformatics Institute (VBI), a world-class research institute dedicated to the study of information biology, is using DataDirect Networks (DDN) SFA® high-performance storage engine-based GRIDScaler GPFS parallel file system to perform rapid, accurate Ebola outbreak modeling for the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA).
A team of 30 researchers and scientists on VBI’s Ebola rapid response team initially provided DTRA and West Africa’s Ministries of Health (MOH) with short-term forecasts on vaccine production and disease spread.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7429756-ddn-gridscaler-vbi-ebola/
Significant advances toward cures for blood cancer patients, many of which were funded by The Leukemia & Lymphoma Society (LLS) over the past 65 years, are among the dramatic highlights featured in Ken Burns presents CANCER: THE EMPEROR OF ALL MALADIES, a film by Barak Goodman, to air on PBS stations nationwide from March 30-April 1. The documentary series is based on the Pulitzer Prize-winning book by Siddhartha Mukherjee, MD, The Emperor of All Maladies: A Biography of Cancer.
LLS has been a driving force behind treatment breakthroughs for patients with blood cancers, including leukemia, lymphoma and myeloma. As the world’s largest voluntary health agency dedicated to finding cures for blood cancer patients, LLS has invested more than $1billion in research to advance lifesaving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7409151-lls-cancer-research-pbs-series/
